Abstract:ObjectiveTo investigate the influencing factors for direct-acting antiviral agent (DAA) therapy failure in the treatment of hepatitis C by comparing baseline clinical data and resistance-associated substitution (RAS) in sequencing data between the patients with HCV RNA reactivation after DAA therapy and the patients with successful DAA treatment. MethodsA total of 13 patients from multiple centers who failed DAA therapy from November 2019 to October 2021 were enrolled as treatment failure group, and sequencing was performed for their positive serum samples. A total of 51 patients with successful DAA treatment were enrolled as control group, and baseline clinical data and sequencing results were compared between the treatment failure group and the control group. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups, and the chi-square test was used for comparison of categorical data between groups; univariate and multivariate logistic regression analyses were performed to calculate odds ratio (OR) and investigate the influencing factors for treatment failure. ResultsAll 12 patients with complete treatment data experienced recurrence within 1 year after the end of medication. The male patients with treatment failure had significantly higher baseline total bilirubin, direct bilirubin, and creatinine than their female counterparts (Z=-2.517, -2.440, and -2.132, P=0.010, 0.010, and 0.038), and the patients with an age of ≤55 years (OR=5.152, 95% confidence interval ［CI］: 1.116-23.790, P=0.036) or genotype 3b (OR=9.726, 95%CI: 1.325-71.398, P=0.025) had a higher probability of treatment failure. There were differences in the incidence rates of major RAS mutations on three gene fragments between the treatment failure group and the treatment success group, and the common RAS mutations detected in the treatment failure group were not detected in the treatment success group. ConclusionAge, genotype, and RAS in serum virus gene sequence are influencing factors for DAA treatment failure.

Mechanism of resistance to direct-acting antivirals in hepatitis C treatment and management

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Research of HCV variants resistant to direct-acting antiviral agents

Advances on Tenofovir for the Treatment of Other Nucleoside Analogue Resistant Chronic Hepatitis B

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6A-Infected Patients.

Safety of direct antiviral agents for treatment of hepatitis C virus infection

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.

Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C

Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C

Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design.

Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Clinical practice of direct-acting antiviral agents for chronic HCV infection

Resistance Mutation During Anti-Hbv and Anti-Hcv Treatment:Question and Strategy

[Selection of Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection].

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents

Hepatitis B Reactivation in Patients Receiving Direct-Acting Antiviral Therapy or Interferon-Based Therapy for Hepatitis C: A Systematic Review and Meta-Analysis